MORRIS LASTER, MD - Kenes

More documents

Recommendations

Info

MORRIS LASTER, MD Page 2 COMPANIES FOUNDED continued 1990 Neose Technologies (Nasdaq: NTEC); Horsham, PA Identified technology, performed due diligence, negotiated license agreement with University of Pennsylvania, wrote initial business plan and recruited management. NASDAQ offering managed by Smith Barney and Vector Securities in 1996. BOARD MEMBERSHIPS Current -BioLineRx -Start-Up Jerusalem- Public Service organization dedicated to promoting economic development of Jerusalem -Course in Pharmaceutical Medicine Tel Aviv University Medical School CLINICAL EXPERIENCE 1993, 1995-1996 Hadassah University Hospital, Jerusalem, Israel Resident, Orthopedic Surgery 1990-1991 Case Western Reserve University Hospital, Cleveland, Ohio Resident, General Surgery MILITARY 1995-Present Israel Defense Forces- Reserve Duty Captain (Res.), Medical Corps 1993-1995 Israel Defense Forces- Active Duty Lieutenant, Physician, Paratrooper Corps EDUCATION 1986-1990 SUNY Health Science Center At Brooklyn (SUNY HSCB); Brooklyn, NY MD; May 15, 1990 Awards University of Texas Medical Branch Surgery Award (1988) Roche Laboratories Award for Excellence in Basic Science Research; First Place - National Student Research Forum (1988) National Institutes of Health Summer Research Fellow (1987) SUNY HSCB Alumni Association Summer Research Award (1987) Engles Scholarship (1987-1990) 1982-1985 State University of New York at Albany; Albany, NY B.S. in Biology; Magna Cum Laude, December 1985
MORRIS LASTER, MD Page 3 BOARD CERTIFICATION 1991 Diplomate National Board of Medical Examiners (USA) Certificate Number 387204 MEDICAL LICENSE 1993 Israeli Medical License Number 26753 1990 Ohio State Medical License Number 062626 PATENTS -An Implantable Device for the Treatment of ESRD and Use Thereof (In submission) -Conjugates Capable of Crossing the Blood-Brain Barrier (US Provisional No 60/674,302) -Bone Marrow as a Site For Transplantation (Granted US 6,463,933, Australia) -Compounds for the Modulation of Kinase Associated Signal Transduction (US Patent Application Ser. No. 10/205302) -Methods Using Glycosaminoglycans For The Treatment of Nephropathy (US Patent Application Ser. No. 11/124,531) -Use of Sulodexide for the Treatment of IBD (US Patent Application Ser. No.10/147681). ASSOCIATIONS BIO Biotechnology Organization Israel Biotechnology Organization American Medical Association Israeli Medical Association American Association for the Advancement of Science American Society for Gene Therapy PUBLICATIONS 1) Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster M, Raz I, Ben Sasson S, Shafrir E, Ziv E. Antidiabetic Effect of Novel Modulating Peptides of G-Protein Coupled Kinase in Experimental Models of Diabetes. Diabetologia. 47:1232-1244 (2004) 2) Niv M, Rubin H, Cohen J, Licht T, Peretzman-Shemer A, Cnaan E, Tartakovski A, Stein I, Albeck S, Tsirulnikov L, Goldenberg-Furmanov M, Weinstein I, Tobi D, Seger R, Laster M, Ben-Sasson SA, Reuveni H. A Novel Technology for Sequence Based kinase inhibitors for therapeutic and target identification applications. J Biol Chem. 279(2):1242-55 (2004) 3) Schachter PP, Ayesh S, Schneider T, Laster M, Czerniak A, Hochberg A. Expression of kinase genes in primary hyperparathyroidism: Adenoma versus hyperplastic parathyroid tissue. Surgery 132(6):1094-9 (2002) 4) Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, deGroot N, Hochberg A. The Possible Physiological Role of H19 RNA. Molecular Carcinogenesis 35(2):63-74 (2002)
Page 1: MORRIS LASTER, MD May, 2007 Home: 1

MORRIS LASTER, MD - Kenes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?